Gastrointestinal Agents Market By Drug Class (Antidiarrheal, Anti-Ulcers, Laxatives, Inflammatory Bowel Disease Irritable Bowel Syndrome) - Growth, Future Prospects And Competitive Analysis 2017 – 2025

Gastrointestinal (GI) symptoms generally include bloating, heartburn, indigestion or dyspepsia, and constipation. According to a new study, almost 74 percent of Americans suffer from digestive symptoms like gas, diarrhea, bloating, and abdominal pain. In this study's scope, gastrointestinal disease or disorder includes gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).

Among the considered conditions, the incidence of GERD is the highest and most commonly observed, followed by IBS and IBD. Thus, the rise in chronic gastrointestinal disorders and diseases, along with the availability of OTC drugs, are driving the growth of the gastrointestinal drug market.

The report titled "Gastrointestinal Agents Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall gastrointestinal agents market, along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on types of drugs and different geographies.

The drug types studied for analyzing the overall global gastrointestinal agents market are majorly segmented into antidiarrheal, anti-ulcer, laxative, inflammatory bowel disease, and irritable bowel syndrome drugs.

Geographically, the global gastrointestinal agents market is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Mexico
  • Brazil
  • Rest of LATAM
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global gastrointestinal agents market.

Tools such as market positioning of key players and appealing investment propositions provide readers with insights into the global gastrointestinal agents market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global gastrointestinal agents market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Based on the type of drug, the global gastrointestinal agents market is segmented as follows:


  • Anti-emetics
  • Anticholinergic Agents
  • Antihistamines
  • Serotonin-5-HT3 Receptor Antagonists
  • cannabinoid receptor antagonists


  • Histamine type 2 receptor blockers (H2 blockers)
  • proton pump inhibitors
  • Laxatives

Inflammatory bowel disease

  • 5-Aminosalicylic Acid (5-ASA) Derivatives
  • Immunosuppressive Agents
  • Tumor Necrosis Factor Antagonists

Irritable bowel syndrome

  • Antimuscarinics/Antispasmodics
  • Prokinetic Agents

Medications for gastrointestinal diseases and symptoms include prescription and nonprescription drugs, conventional and unconventional agents, simple small molecules, complex macromolecules, and large recombinant proteins.

Because of the disease's high prevalence in the region, inflammatory bowel disease held the largest share of the gastrointestinal agents market in 2016. While irritable bowel syndrome is anticipated to grow at the highest CAGR during the forecast period,

For the purpose of this study, the global gastrointestinal agents market is geographically categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

At present, North America dominates the global market for gastrointestinal agents. The United States, in particular, holds the largest market share in the regional gastrointestinal agents market. However, the region is expected to witness flat growth due to the maturity of this market and no anticipated competition from potential drugs.

Europe is considered to be the second-largest market for gastrointestinal agents. Asia Pacific is anticipated to be the fastest-growing market in the forecast period. The Asia Pacific market is being driven by rising gastrointestinal disease and disorder incidence, technological advancement, and overall improvement in healthcare infrastructure in emerging economies. 

Frequently Asked Question:

The market for Gastrointestinal Agents Market is expected to reach USD$ 21,177.7 Mn in 2025.

The Gastrointestinal Agents Market is expected to see significant CAGR growth over the coming years, at 2.6%.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

Abbott Laboratories,Allergan Plc. (Formerly Actavis Plc.),AstraZeneca,Bayer AG. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  May 2017
Category:  Pharmaceuticals
Report ID:   58473
Report Format:   PDF
Pages:   120
Rating:    4.5 (50)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support